Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
HAE

Haemonetics Corp

HAE

81.98USD+0.04 (+0.05%)Market Closed
Watchlist

Market Summary

USD81.98+0.04
Market Closed
0.05%

HAE Stock Price

View Fullscreen

HAE RSI Chart

HAE Valuation

Market Cap

4.2B

Price/Earnings (Trailing)

32.41

Price/Sales (Trailing)

3.36

EV/EBITDA

15.06

Price/Free Cashflow

20.88

HAE Price/Sales (Trailing)

HAE Profitability

EBT Margin

12.10%

Return on Equity

14.11%

Return on Assets

5.96%

Free Cashflow Yield

4.79%

HAE Fundamentals

HAE Revenue

Revenue (TTM)

1.2B

Revenue Y/Y

6.96%

Revenue Q/Q

2.2%

HAE Earnings

Earnings (TTM)

128.3M

Earnings Y/Y

-24.97%

Earnings Q/Q

-39.31%

Price Action

Last 7 days

-1.8%

Last 30 days

-3.8%

Last 90 days

-7.6%

Trailing 12 Months

-2.9%

How does HAE drawdown profile look like?

HAE Financial Health

Current Ratio

3.06

HAE Investor Care

Shares Dilution (1Y)

0.27%

Diluted EPS (TTM)

2.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.2B1.2B1.2B0
2022993.2M1.0B1.1B1.1B
2021870.5M903.4M933.8M953.2M
2020988.5M945.6M902.5M883.9M
2019967.6M976.7M987.7M999.3M
2018903.9M922.3M938.5M951.8M
2017886.1M887.1M892.2M898.4M
2016908.8M905.4M905.9M900.4M
2015910.4M899.3M891.4M893.0M
2014938.5M943.5M935.3M925.0M
2013892.0M935.1M952.6M947.4M
2012727.8M733.8M772.5M828.7M
2011676.7M684.2M696.8M711.2M
2010645.4M654.4M664.1M675.8M
2009597.9M609.8M621.7M633.5M

Latest Insider Trading transactions for HAE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 01, 2023
galvin roy
sold (taxes)
-13,822
86.39
-160
president, global plasma & bc
Oct 20, 2023
strong stewart w
sold (taxes)
-10,686
89.05
-120
president, global hospital
Oct 20, 2023
basil michelle l
sold (taxes)
-17,542
89.05
-197
evp and general counsel
Sep 15, 2023
miller laurie a.
sold (taxes)
-18,833
90.11
-209
svp, human resources
Sep 12, 2023
strong stewart w
sold
-20,668
90.65
-228
president, global hospital
Sep 11, 2023
lingamneni anila
sold
-207,450
90.00
-2,305
evp, chief technology officer
Sep 05, 2023
dockendorff charles j
sold
-895,651
87.68
-10,215
-
Aug 04, 2023
bryant diane m
acquired
-
-
2,226
-
Aug 04, 2023
dockendorff charles j
acquired
-
-
2,226
-
Aug 04, 2023
kroll mark w
acquired
-
-
2,226
-

1–10 of 50

Which funds bought or sold HAE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-1.5
638,449
18,173,500
0.01%
Nov 22, 2023
Graham Capital Management, L.P.
sold off
-100
-482,062
-
-%
Nov 21, 2023
Walleye Capital LLC
new
-
202,182
202,182
-%
Nov 21, 2023
COMERICA BANK
reduced
-21.72
1,909,310
1,910,310
0.01%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
sold off
-100
-15,108,900
-
-%
Nov 16, 2023
Financial Gravity Asset Management, Inc.
sold off
-100
-730
39.00
-%
Nov 16, 2023
Orion Capital Management LLC
new
-
23,828
23,828
0.01%
Nov 15, 2023
HARBOUR INVESTMENTS, INC.
unchanged
-
222
4,479
-%
Nov 15, 2023
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
reduced
-0.6
11,000
253,000
-%
Nov 15, 2023
Toroso Investments, LLC
added
12.19
60,571
396,571
0.01%

1–10 of 40

Latest Funds Activity

Are funds buying HAE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HAE
No. of Funds

Schedule 13G FIlings of Haemonetics Corp

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital research global investors
11.8%
5,956,064
SC 13G/A
Feb 09, 2023
vanguard group inc
10.36%
5,242,836
SC 13G/A
Feb 06, 2023
wellington management group llp
7.97%
4,034,753
SC 13G/A
Jan 26, 2023
blackrock inc.
11.7%
5,898,620
SC 13G/A
Jan 20, 2023
blackrock inc.
11.7%
5,898,620
SC 13G/A
Apr 08, 2022
capital research global investors
10.7%
5,452,006
SC 13G
Feb 14, 2022
neuberger berman group llc
7.59%
3,876,521
SC 13G/A
Feb 11, 2022
capital research global investors
4.0%
2,049,133
SC 13G/A
Feb 10, 2022
vanguard group inc
9.55%
4,880,936
SC 13G/A
Feb 10, 2022
wellington management group llp
10.83%
5,537,538
SC 13G/A

Recent SEC filings of Haemonetics Corp

View All Filings
Date Filed Form Type Document
Nov 03, 2023
4
Insider Trading
Nov 02, 2023
8-K
Current Report
Nov 02, 2023
10-Q
Quarterly Report
Oct 24, 2023
4
Insider Trading
Oct 24, 2023
4
Insider Trading
Oct 12, 2023
8-K/A
Current Report
Oct 10, 2023
8-K
Current Report
Sep 18, 2023
4
Insider Trading
Sep 13, 2023
4
Insider Trading
Sep 13, 2023
4
Insider Trading

Peers (Alternatives to Haemonetics Corp)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
179.2B
40.0B
10.05% -2.88%
34.72
4.48
-11.26% -34.57%
71.3B
19.4B
-6.71% 1.22%
44.09
3.79
2.66% -16.58%
18.2B
15.0B
11.91% -35.29%
7.03
1.21
3.01% 209.09%
16.8B
3.8B
-13.48% 11.82%
46.33
4.42
-1.48% -28.97%
MID-CAP
9.1B
12.6B
2.80% -13.35%
19.86
0.72
-0.94% -29.54%
9.1B
2.7B
7.69% -22.67%
-57.06
3.34
-3.01% 97.36%
8.4B
3.4B
4.90% 20.89%
30
2.45
3.13% 18.17%
6.6B
3.9B
-1.54% 1.10%
-30.43
1.69
-2.62% 73.28%
3.1B
6.5B
5.03% 11.86%
14.6
0.48
1.83% 10.70%
2.9B
342.6M
11.80% -12.52%
-240.39
8.41
42.19% 84.14%
SMALL-CAP
1.2B
3.1B
19.36% -60.32%
-2.73
0.37
7.95% -550.16%
310.6M
163.3M
13.17% -30.31%
-12.64
1.9
7.14% -56.09%
280.7M
335.9M
7.28% -49.08%
43.55
0.84
4.71% 116.39%
88.3M
50.3M
4.17% 45.35%
-5.83
1.76
3.23% 20.81%
4.2M
3.8M
13.42% -61.23%
-0.36
1.11
17.30% 10.67%

Haemonetics Corp News

Latest updates
msnNOW27 Nov 202303:32 pm7 hours ago
Stocks Register25 Nov 202303:35 pm2 days ago
Stocks Register18 Nov 202312:33 pm9 days ago
San Francisco Chronicle02 Nov 202307:00 am25 days ago
Nasdaq25 Oct 202307:00 am33 days ago
The Business Journals10 Oct 202307:00 am48 days ago
StockNews.com20 Jul 202307:00 am4 months ago
The Business Journals24 Jun 202207:00 am17 months ago
Banyan Hill Publishing08 Feb 202208:00 am21 months ago
ThinkMarkets15 Jun 202104:37 pm2 years ago
TMS Brokers13 May 202104:04 pm2 years ago
AsiaOne28 May 202007:00 am3 years ago
The Business Journals11 Dec 201908:00 am3 years ago
TMS Brokers16 Nov 201904:39 pm4 years ago
TMS Brokers09 Mar 201811:44 am5 years ago

Financials for Haemonetics Corp

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue2.2%318311304305297261265260240229225240209196238259253238249247242
Gross Profit1.9%17116715615915814213613912310882.0012010690.00114128127116111111112
Operating Expenses19.0%13511412111511111111710398.0010710380.0047.0078.0088.0087.0077.0012987.0083.0086.00
  S&GA Expenses12.2%10593.0097.0095.0092.0092.0092.0081.0076.0091.0084.0066.0064.0062.0053.0078.0078.0073.0054.0074.0077.00
  R&D Expenses0.1%13.0013.0016.0013.0011.0011.0013.0010.0011.0013.0011.008.007.008.009.007.007.007.009.009.009.00
EBITDA Margin---0.21*-0.19*0.18*0.17*0.13*0.13*0.17*0.19*0.25*0.26*0.24*0.21*0.21*0.20*----
Interest Expenses----------1.002.001.002.003.002.004.003.004.004.004.003.00
Income Taxes-24.5%8.0011.003.009.008.006.006.008.005.001.00-16.385.007.00-2.554.008.008.00-9.251.007.004.00
Earnings Before Taxes-36.4%33.0052.0033.0042.0041.0025.0015.0031.0020.00-3.01-27.4037.0055.008.0022.0038.0045.00-17.7322.0025.0023.00
EBT Margin---0.12*0.11*0.10*0.09*0.06*0.02*0.03*0.07*0.08*0.14*0.14*0.12*0.09*0.09*-----
Net Income-39.3%25.0041.0029.0033.0033.0020.0010.0023.0015.00-4.45-11.0432.0048.0011.0018.0030.0037.00-8.4821.00-8.4819.00
Net Income Margin---0.10*0.08*0.08*0.07*0.04*0.02*0.03*0.07*0.09*0.12*0.12*0.10*0.08*0.08*-----
Free Cashflow---68.0048.0051.00-3.4733.0036.0023.00-15.60-10.0957.0021.004.0036.0059.00-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets2.5%2,0111,9621,9351,8781,8651,8211,8601,8311,8011,7941,8201,3181,4181,4331,2671,2381,1911,2601,2751,2281,266
  Current Assets8.0%866802770706716688756729699684694668760759604583568615576516553
    Cash Equivalents22.8%351286284224241215259237192173192189279276137126112190169155200
  Inventory-1.2%286289259256255278293306323327323300305295270254245222194169164
  Net PPE1.1%308304311313308288258239224215218240240243253268264277344351345
  Goodwill-0.1%4654664664664654664674684694664662162152178.00211211211211211211
  Current Liabilities11.5%264237252227262180442355288228253194339408275257240294236211189
    LT Debt, Current0.0%14.0014.0012.0010.0058.007.0021414483.0017.0017.0017.0016723177.0062.0057.0011828.0017.0013.00
    LT Debt, Non Current-0.4%749751754757760763559633698767691293297297306310314318322327331
Shareholder's Equity3.4%894865818776729770749731699677732719668609587575584591668591701
  Retained Earnings8.8%30928425322420422220219316915515816913789.0079.0070.0086.0099.00161141194
  Additional Paid-In Capital1.2%617610595587564580572567558551603579569563553538534525536531530
Shares Outstanding0.1%51.0051.0050.0050.0051.0051.0051.0051.0051.0051.0051.0051.0051.0050.0050.0051.0051.0051.0051.0051.0052.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations419.4%99,124,00019,086,00079,611,00064,415,00087,039,00041,993,00068,050,00062,433,00043,460,000-1,680,0001,547,00066,291,00029,155,00011,812,00046,406,00079,282,00029,901,0002,628,00020,638,00058,164,00057,357,000
  Share Based Compensation-4.0%6,706,0006,989,0007,058,0007,491,0005,735,0005,299,0005,097,0006,455,0005,979,0006,828,0007,110,0006,287,0005,952,0006,167,0005,399,0005,325,0005,000,0004,730,0004,445,0004,782,0004,582,000
Cashflow From Investing-64.7%-25,135,000-15,261,000-18,006,000-36,500,000-31,068,000-58,214,000-34,512,000-15,462,000-20,520,000-15,851,000-429,100,000-9,581,00037,135,000-23,896,000-45,135,000-19,866,0005,964,0001,861,000-13,217,000-27,585,000-48,082,000
Cashflow From Financing-1099.3%-7,172,000-598,000-1,603,000-49,680,000-25,686,000-23,395,000-8,765,000-2,035,000-3,315,000-1,634,000432,759,000-149,940,000-64,318,000148,951,00011,372,000-46,153,000-112,517,00016,090,0006,995,000-76,207,000-79,000
  Buy Backs-----75,000,000----------50,000,00050,000,00075,000,0002,500,00075,000,000-

HAE Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Sep. 30, 2023
Oct. 01, 2022
Sep. 30, 2023
Oct. 01, 2022
Income Statement [Abstract]    
Net revenues$ 318,183$ 297,485$ 629,515$ 558,943
Cost of goods sold147,673139,607291,740258,802
Gross profit170,510157,878337,775300,141
Operating expenses:    
Research and development12,66510,89625,31321,798
Selling, general and administrative104,90192,029198,386184,256
Amortization of acquired intangible assets7,2228,22114,69516,588
Impairment of assets10,419010,4190
Total operating expenses135,207111,146248,813222,642
Operating income35,30346,73288,96277,499
Interest and other expense, net(2,471)(5,673)(4,540)(10,946)
Income before provision for income taxes32,83241,05984,42266,553
Provision for income taxes7,9247,86218,47213,479
Net income$ 24,908$ 33,197$ 65,950$ 53,074
Basic income (loss) per share (in dollars per share)$ 0.49$ 0.65$ 1.30$ 1.04
Diluted income (loss) per share (in dollars per share)$ 0.48$ 0.64$ 1.28$ 1.03
Weighted average shares outstanding    
Basic (in shares)50,72750,95350,63451,089
Diluted (in shares)51,39651,55851,36851,620
Comprehensive income$ 21,721$ 25,659$ 63,626$ 38,773

HAE Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Apr. 01, 2023
Current assets:  
Cash and cash equivalents$ 351,005$ 284,466
Accounts receivable, less allowance for credit losses of $5,044 at September 30, 2023 and $4,932 at April 1, 2023174,249179,142
Inventories, net285,830259,379
Prepaid expenses and other current assets54,66046,735
Total current assets865,744769,722
Property, plant and equipment, net307,766310,885
Intangible assets, less accumulated amortization of $433,092 at September 30, 2023 and $417,422 at April 1, 2023250,504275,771
Goodwill465,405466,231
Deferred tax asset4,7455,241
Other long-term assets117,111106,975
Total assets2,011,2751,934,825
Current liabilities:  
Notes payable and current maturities of long-term debt13,56611,784
Accounts payable80,16063,929
Accrued payroll and related costs45,63864,475
Other current liabilities124,851111,628
Total current liabilities264,215251,816
Long-term debt, net of current maturities748,662754,102
Deferred tax liability34,80736,195
Other long-term liabilities69,93174,715
Stockholders’ equity:  
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 50,740,389 shares at September 30, 2023 and 50,448,519 shares at April 1, 2023507504
Additional paid-in capital616,960594,706
Retained earnings308,898253,168
Accumulated other comprehensive loss(32,705)(30,381)
Stockholders’ equity:893,660817,997
Total liabilities and stockholders’ equity$ 2,011,275$ 1,934,825
HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEwww.haemonetics.com
 EMPLOYEES3034

Haemonetics Corp Frequently Asked Questions


What is the ticker symbol for Haemonetics Corp?

Ticker symbol for Haemonetics Corp is HAE.

What is the market capital of Haemonetics Corp (HAE)?

As of Fri Nov 24 2023, market cap of Haemonetics Corp is 4.16 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HAE stock?

You can check HAE's fair value in chart. The fair value of Haemonetics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Haemonetics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HAE so that you know how good or bad the model has been in the past so you can discard it if needed.

Is Haemonetics Corp stock overpriced or underpriced?

The fair value guage provides a quick view whether HAE is over valued or under valued. Whether Haemonetics Corp is cheap or expensive depends on the assumptions which impact Haemonetics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HAE.

What is Haemonetics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 24 2023, HAE's PE ratio (Price to Earnings) is 32.41 and Price to Sales (PS) ratio is 3.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HAE PE ratio will change depending on the future growth rate expectations of investors.